M
Mellon Medical
One-handed precision suturing device for safer and faster vascular surgeries
About Mellon Medical
Mellon Medical, established in 2013, is a Dutch medical technology company focused on advancing surgical suturing. The company was founded by vascular surgeon Mark Vrancken Peeters, who transitioned from his surgical practice to become the Chief Medical Officer of Mellon. This career change was driven by his belief that single-handed suturing could significantly improve procedural outcomes and his ambition to impact more than one patient at a time. In April 2024, Mellon Medical became part of the Demcon Group, a move intended to further support the development of its core product.
The company has developed a platform technology centered around one-handed suturing, with its leading product being the Switch®, a disposable, precision-suturing instrument. This Class III medical device operates with a simple pinch of the thumb and index finger, freeing the surgeon's other hand to present the tissue. The device uses a straight, double-pointed needle that moves between two jaws, a mechanism designed to be faster and more precise than conventional suturing, which requires passing a curved needle between instruments. The Switch® is designed to facilitate the 'small bites' suturing technique, particularly for closing the abdominal wall, which research has shown can significantly reduce postoperative complications like incisional hernias. Its pencil-like shape and balanced weight are intended to provide ergonomic use for both right- and left-handed surgeons.
Mellon Medical targets the global surgical suture and devices market, which was estimated to be worth over $3 billion. The company's business model revolves around the sale of its disposable Switch® device and accompanying suture sets. While the initial focus is on vascular surgery—specifically procedures like carotid artery surgery and kidney transplants—Mellon's technology is a platform applicable to a wide range of disciplines, including general surgery, gynecology, and urology. The company has secured approximately $7.1 million in funding through Series A and Series B rounds, with key investors including BioGeneration Ventures, Thuja Capital, and Oost NL. Mellon is collaborating with the Erasmus Medical Center for clinical validation and has partnered with Assut for the development and production of its suture sets.
Source: Dealroom company dataNews
Open roles
Mellon Medical in the Nijmegen ecosystem
The Mellon Medical office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
Thuja Capital
BioGeneration Ventures
Oost NL - Eastern Netherlands Regional Development Agency
David Pyott
BOM - Brabant Regional Development Agency
Series B and later1 investor entered at this stage
Demcon
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Mellon Medical on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Mellon Medical on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.


